Hematology was established as an independent department in 2002 and became a key discipline in the hospital in 2003. Former directors of the Hematology Department have come from well-known hematology experts in China, such as the Chinese Academy of Sciences and Peking University. Starting from the clinical diagnosis and differential diagnosis of hematological diseases, they have established standardized diagnosis and treatment from basic laboratories to various diseases, and focused on the standardized application of key technologies such as hematopoietic stem cell transplantation. Gradually, they have formed a blood sub specialty based on leukemia, lymphoma, multiple myeloma, cell immunotherapy, and hematopoietic stem cell transplantation, and trained a group of young and middle-aged experts with solid clinical foundations and a spirit of dedication. In 2016, relying on three engineering projects in Shenzhen, Professor Huang Xiaojun's hematology team from Peking University's Institute of Hematology was introduced.
At present, the department has a total of 41 medical staff, including 3 chief physicians, 6 deputy chief physicians, 4 attending physicians, and 4 resident doctors. Three master's supervisors. 4 PhD holders, 11 Master's degree holders, and 2 Bachelor's degree holders. All enrolled physicians have received standardized training as resident physicians at Peking University and have studied at the Institute of Hematology at Peking University People's Hospital, Tokyo Cancer Institute Hospital in Japan, and Miami Medical Center in the United States.
The Hematology Department mainly treats various blood tumors including leukemia, lymphoma, and myeloma, as well as serious blood system diseases that threaten human health such as myelodysplastic disorders, aplastic anemia, and coagulation. It is one of the earliest units in Shenzhen to carry out hematopoietic stem cell transplantation. At present, there are three functional wards: Blood General Ward, Daytime Chemotherapy Ward, and Transplantation Ward. There are 38 beds in the General Ward and 8 beds in the Daytime Ward. The Hematopoietic Stem Cell Transplantation Ward has 10 high standard Class 100 laminar flow purification wards, 3 blood cell separators, and sub specialty clinics for leukemia, malignant lymphoma, multiple myeloma, cell immunotherapy, and hematopoietic stem cell transplantation. Since its establishment 22 years ago, the department has always adhered to the goal of "putting patients at the center and treating for cure". General medical staff serve the vast number of blood disease patients wholeheartedly with good teamwork and pragmatic dedication, and enjoy a high reputation in Shenzhen and surrounding areas.
Precision Diagnosis System for Hematological Tumors: The Hematology Department, in collaboration with the Hematology Department, Immunology Department, Molecular Genetics Department, and Hematological Tumor Pathology Department of Peking University Shenzhen Hospital, has established a precise MICM typing system for hematological tumors. At the same time, Jin Yu Hematology Testing provides a wider range of personalized molecular genetic testing, ensuring standardized diagnosis and treatment of hematological tumors, precise targeting and transplantation technology applications, and overall treatment of cellular immunotherapy.
Various sub specialties of hematological malignancies: We have cultivated five sub specialties including leukemia, lymphoma, myeloma, cell immunotherapy, and hematopoietic stem cell transplantation. We have established a complete modern diagnostic and treatment technology system for various acute and chronic leukemia, malignant lymphoma, and multiple myeloma. In practice, we have formed a standardized treatment based on prognosis stratification, including standardized induction consolidation therapy, maintenance therapy, hematopoietic stem cell transplantation, and comprehensive follow-up management as a whole treatment strategy. We are the first to establish a lymphoma specialty alliance in Shenzhen. And a multidisciplinary collaborative team (MDT) was formed to provide early diagnosis and treatment of difficult to treat diseases across specialties.
Hematopoietic stem cell transplantation: Established mature non blood donor and haploid donor transplantation techniques, with efficacy equivalent to sibling identical transplantation, standardized dynamic stratification before transplantation, transplantation timing and protocol selection, post transplant virus infection prevention and treatment system, comprehensive diagnosis and treatment of non infectious pulmonary complications, etc. Exploring the combination of CART and hematopoietic stem cell transplantation for the treatment of refractory lymphoma and leukemia, including PICC management, monitoring of drug-resistant bacteria and antibiotic susceptibility, prevention of hospital acquired infections, and actively carrying out comprehensive nursing care including patient nutrition and psychology. The transplantation diseases cover leukemia, myelodysplastic syndrome, severe aplastic anemia, lymphoma, multiple myeloma and other benign and malignant diseases of the hematopoietic system, and the therapeutic effect has reached a high level in the province, leading the way in Shenzhen. In 2007, it passed the review of the Guangdong Provincial Expert Group and obtained the qualification for admission to the Ministry of Health's non blood related hematopoietic stem cell transplantation hospital. And it has become a Chinese bone marrow transplant bank and a Taiwan Tzu Chi bone marrow unrelated hematopoietic stem cell transplant unit. As the oldest hematopoietic stem cell transplantation unit in Shenzhen, it has completed more than 400 cases of hematopoietic stem cell transplantation patients, with an overall 5-year generation time of over 70%. Reaching the leading level domestically. Hematopoietic stem cell transplantation has been consistently used in clinical practice to treat patients with refractory leukemia, myelodysplastic syndrome, lymphoma, and multiple myeloma.
CAR-T cell immunotherapy: The first clinical study on CAR-T cell immunotherapy for relapsed and refractory malignant hematological tumors was conducted in South China. Since its establishment, 61 subjects have been enrolled, providing a new treatment approach for a group of advanced refractory hematological disease patients and prolonging their survival. Especially in 2019, the world's first successful case of CD4 CAR T cell therapy for relapsed refractory peripheral T-cell lymphoma was presented at the ASH American Hematology Annual Meeting that year. In 2020, the first case of BCMA-CD19 combined with CART cell therapy for diffuse large B-cell lymphoma complicated with active systemic lupus erythematosus was completed, and complete remission was achieved. Clinical trials of CARTCD5 and CARTCD7 in T-cell tumors were actively explored.
In the future, the department is committed to establishing the most comprehensive blood disease diagnosis, treatment, research, and teaching hub center in Shenzhen, which can provide the highest quality medical services, continue to develop cutting-edge medical technologies, build high-level scientific research platforms, strengthen translational and applied research, and provide cutting-edge, evidence-based, patient-centered advanced medical and nursing models for blood disease patients.